Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: padco who wrote (13718)	10/7/2004 12:51:24 PM
From: axial	Respond to of 14101

"...that woman couldn't raise money on Bay street, and for good reason, no one trusted her." Padco, good post. You correctly point out how the "web" got woven around the inability to get cost-effective financing. "...She couldn't tell us why Pennsaid was floundering at the FDA, because she knew she couldn't raise the money to do the trials they wanted. She couldn't speed the WF10 data collection along because she couldn't get the money to do the work. Recently, she couldn't tell us that she was spending eight times the returns to sell Pennsaid in Britian. Why, because the good ship Dimethaid couldn't absorb many more blows..." Yes. The NEXT question, the important question that remains to be answered is, "What caused that loss of trust?" Was it simply the perception of bad management, or was it something more specific? What caused Tom Stanley's abrupt turnaround? What caused The Street to say "Thanks, but no thanks" to RK? After all, The Street isn't known for being particular about where - or how - it makes money. Being beneath The Street's "standards" has some dark implications. Perhaps it's all appearances - but the appearances don't look good. Jim

To: padco who wrote (13718)	10/7/2004 12:59:15 PM
From: SofaSpud	Respond to of 14101

I agree that the fact of disclosure is very, very encouraging. It's almost as if the average investor might be able to make an informed decision, what a switch <g>. I'd actually freed up some cash yesterday, before the NR, with an eye toward getting back in. The news that Pennsaid won't be in the US for three years, though, is quite major IMO. Unless the lack of growth in Canada is somehow reversed, we're not looking at cash-flow positive operation for some time. I may believe in the products, and in the potential of WF10, but just at the moment I don't see ROI in the next three years. Oh, down the road a bit, sure, if they can raise money to prove up WF10, and once it seems clear that the FDA reservations on Pennsaid can be overcome, somebody could take DMX out, and probably at a very nice premium over today's 60 cents. But in the next year? Two years? Don't get me wrong -- I'm emphatically onside with the idea that things are better today than they were a month ago. Just not enough better to get me off the sidelines just yet. And to all those who are braver than I, sincere good wishes. FWIW